Composition for treatment of vitiligo

ABSTRACT

A composition for treating vitiligo and a method of making the same, said composition comprising: a blue scorpion venom; and an alpha lipoic acid. Preferably, the blue scorpion venom is diluted, polarized, and nanosized. Preferably the alpha lipoic acid is polarized and nanosized. The composition may also comprise various vitamins and minerals.

CROSS-REFERENCE TO RELATED APPLICATIONS

This U.S. Non-Provisional Patent Application is a Continuation-in-PartPatent Application of U.S. Non-Provisional patent application Ser. No.14/632,973, filed on Feb. 26, 2015, titled “Polarized Scorpion VenomSolution and a Method for Making Polarized Scorpion Venom Solution,” bysole inventor Arthur Mikaelian, the contents of which are expresslyincorporated herein by this reference as though set forth in theirentirety, and to which priority and benefit are claimed. U.S.Non-Provisional patent application Ser. No. 14/632,973 is a ContinuationApplication of U.S. Non-Provisional patent application Ser. No.13/849,008, filed on Mar. 22, 2013, titled “Polarized Scorpion VenomSolution and a Method for Making Polarized Scorpion Venom Solution,” bysole inventor Arthur Mikaelian, the contents of which are expresslyincorporated herein by this reference as though set forth in theirentirety. U.S. Non-Provisional patent application Ser. No. 13/849,008 isa Continuation Application of U.S. Non-Provisional patent applicationSer. No. 13/323,669, filed on Dec. 12, 2011, titled “Polarized ScorpionVenom Solution and a Method for Making Polarized Scorpion VenomSolution,” by sole inventor Arthur Mikaelian, the contents of which areexpressly incorporated herein by this reference as though set forth intheir entirety. U.S. Non-Provisional patent application Ser. No.13/323,669 is a Continuation Application of U.S. Non-Provisional patentapplication Ser. No. 12/270,664, now U.S. Pat. No. 8,097,284, filed onNov. 13, 2008, titled “Polarized Scorpion Venom Solution and a Methodfor Making Polarized Scorpion Venom Solution,” by sole inventor ArthurMikaelian, the contents of which are expressly incorporated herein bythis reference as though set forth in their entirety. U.S.Non-Provisional patent application Ser. No. 12/270,664 claims priorityfrom and benefit of U.S. Provisional Patent Application No. 60/987,756,filed on Nov. 13, 2007, titled “Analgesic, Antiinflammatory, ImmunityBoosting, Antitumoral, and Cancer Preventing and Treating MethodologyUsing Organic, Modified, and Magnetically Polarized Scorpion Venom andSynthetics Thereof,” by sole inventor Arthur Mikaelian, the contents ofwhich are expressly incorporated herein by this reference as though setforth in their entirety.

FIELD

The present disclosure relates generally to a pharmaceutical ortherapeutic composition for treating diseases associated with pigmentloss. More specifically, the present disclosure relates to a compositioncomprising polarized and nanosized blue scorpion venom and polarized andnanosized alpha lipoic acid, a method of manufacture thereof, and amethod of administration of that composition for treating Vitiligo.

BACKGROUND

Vitiligo is due to the loss or destruction of melanocytes, which are thecells that produce melanin. Melanin determines the color of anindividual's skin, hair, and eyes. If melanocytes cannot form melanin orif the number of melanocytes decreases, skin, hair, and eye color maybecome progressively lighter.

The exact cause of Vitiligo is unknown, but there are three maintheories on what might be the cause: 1) the pigment cells are injured byabnormally functioning nerve cells; 2) there is an autoimmune reactionagainst the pigment cells; or 3) the pigment cells self-destruct.

Vitiligo affects 0.5% to 1% of the population, and occurs in all races.It may be more common in certain locations, such as India, with reportsof up to 8.8% of the population affected. In about 50% of affectedindividuals, pigment loss begins before the age of 20 years old, and inabout 80% of affected individuals, pigment loss begins before the age of30 years old. In about 20% of affected individuals, Vitiligo is presentin one or more other members of that person's family. Males and femalesappear to be equally affected by Vitiligo.

Even though most individuals with Vitiligo are in good health, they mayface a greater risk of autoimmune diseases such as diabetes, thyroiddisease, pernicious anemia (B12 deficiency), Addison's disease (adrenalgland disease), systemic lupus erythematosus, rheumatoid arthritis,psoriasis, and alopecia areata (round patches of hair loss).

Currently, there is no cure for Vitiligo but several treatment optionsare available. An affected individual may use applied steroids andultraviolet light (phototherapy). However, due to the high risk of skincancer associated with phototherapy, the United Kingdom's NationalHealth Service suggests that phototherapy only be used if primarytreatments are ineffective. Lesions located on the hands, feet, andjoints are typically the most difficult to repigment and those on theface are easiest to return to the natural skin color.

Thus, there exists the need for an effective solution to treat Vitiligoand other diseases associated with pigment loss.

SUMMARY

To minimize the limitations in the cited references, and to minimizeother limitations that will become apparent upon reading andunderstanding the present specification, the present specificationdiscloses a polarized scorpion venom solution useful for the treatmentof Vitiligo and other diseases associated with pigment loss.

One embodiment may be a composition for treating vitiligo, thecomposition comprising: a blue scorpion venom; and an alpha lipoic acid.The blue scorpion venom may be diluted in a distilled water, such that adilute blue scorpion venom is created. The dilute blue scorpion venommay be polarized, such that a polarized blue scorpion venom is created;and wherein the alpha lipoic acid may be polarized, such that apolarized alpha lipoic acid is created. The polarized blue scorpionvenom may be polarized by circulating the dilute blue scorpion venombetween at least one set of two paired and aligned magnets; and whereinthe alpha lipoic acid is polarized by circulating the alpha lipoic acidbetween the at least one set of two paired and aligned magnets. Each setof magnets of the at least one set of two paired and aligned magnets maymirror each other, such that the magnets repel each other. The polarizedblue scorpion venom and the polarized alpha lipoic acid may benanosized. A particle size reduction machine may be used to nanosize thepolarized blue scorpion venom and the polarized alpha lipoic acid, suchthat a polarized and nanosized blue scorpion venom is created and apolarized and nanosized alpha lipoic acid is created. The at least oneset of two paired and aligned magnets are operatively coupled to a powersource, such that a frequency of the at least one set of two paired andaligned magnets is set. The polarized and nanosized blue scorpion venomand the polarized and nanosized alpha lipoic acid may comprise the twoactive ingredients of the composition, and the composition may beingested orally by a patient suffering from vitiligo as part of atreatment regimen, such that the patient's skin has an enhancedre-pigmentation as a result of the treatment. The composition mayfurther comprises: one or more vitamins The one or more vitamins maycomprise: vitamin B1; vitamin B3; vitamin B6; vitamin B7; vitamin B12;vitamin C; vitamin D3; and vitamin E. The composition may furthercomprise one or more minerals. The one or more minerals comprise: zincgluconate; copper gluconate; potassium sorbate; and potassium benzoate.The polarized and nanosized blue scorpion venom may be in an amount from0.001 to 0.005 percent by weight based on a total weight of thecomposition. The polarized and nanosized blue scorpion venom is in anamount of 0.003 percent by weight based on a total weight of thecomposition. The polarized and nanosized alpha lipoic acid may be in anamount from 1.0 to 2.0 percent by weight based on a total weight of thecomposition. The polarized and nanosized alpha lipoic acid may be in anamount of 1.58 percent by weight based on a total weight of thecomposition.

Another embodiment may be method of treating vitiligo comprising thesteps: creating a vitiligo treatment composition comprising: a bluescorpion venom and an alpha lipoic acid; wherein the vitiligo treatmentcomposition is ingested orally by a patient suffering from vitiligo aspart of a treatment regimen, such that the patient's skin has anenhanced re-pigmentation. The steps may further comprise: diluting theblue scorpion venom to create a dilute blue scorpion venom; polarizingthe dilute blue scorpion venom to create a polarized blue scorpionvenom; polarizing the alpha lipoic acid to create a polarized alphalipoic acid; nanosizing the polarized blue scorpion venom to create apolarized and nanosized blue scorpion venom; and nanosizing thepolarized alpha lipoic acid to create a polarized and nanosized alphalipoic acid. The polarized blue scorpion venom and the polarized alphalipoic acid may be polarized by a polarization method comprising thesteps: providing one or more tubes that are configured to allow thepolarized blue scorpion venom or the polarized alpha lipoic acid tocirculate through; providing one or more pairs of magnets, wherein eachpair of the one or more pairs of magnets are aligned and spaced apart,such that one of the one or more tubes is sandwiched between the one ormore aligned pairs of magnets; circulating the diluted blue scorpionvenom through the one or more tubes; and circulating the alpha lipoicacid through the one or more tubes. The nanosizing may comprise thesteps: providing a particle size reduction machine; adding the polarizedblue scorpion venom to the particle size reduction machine, such that apolarized and nanosized blue scorpion venom is created; and adding thepolarized alpha lipoic acid to the particle size reduction machine suchthat a polarized and nanosized alpha lipoic acid is created.

in one embodiment, the composition may substantially halt theprogression of vitiligo, restore melanocytes, and/or restore the normalfunction of T-cells, such that the T-cells no longer recognizemelanocytes as foreign to the body.

In one embodiment, the composition may comprise active ingredients ofalpha lipoic acid and the venom extract of the Rhopalurus princepsscorpion (Blue Scorpion). Preferably, the active ingredients arepolarized and/or nanosized. The alpha lipoic acid is an organosulfurcompound that has antioxidant properties, which has been shown toprevent or alleviate symptoms of vitamins A and E deficiencies. Alphalipoic acid may he used to take up reactive oxygen and nitrogen, whichmakes alpha lipoic acid an excellent compound to help reduce theoxidative stress in the skin and prevent the destruction of melanocytesby the harmful free radicals.

In a preferred embodiment, the composition may be mixture of thepolarized scorpion venom, the polarized alpha lipoic acid, and variousvitamins and supplements.

It is an object of the present disclosure to overcome the limitations ofthe prior art.

Additional embodiments of the disclosure will be understood from thedetailed description of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawings show illustrative embodiments, but do not depict allembodiments. Other embodiments may be used in addition to or instead ofthe illustrative embodiments. Details that may be apparent orunnecessary may be omitted for the purpose of saving space or for moreeffective illustrations. Some embodiments may be practiced withadditional components or steps and/or without some or all components orsteps provided in the illustrations. When different drawings contain thesame numeral, that numeral refers to the same or similar components orsteps.

FIG. 1 is an illustration of a particle size reduction machine, such asa Microfluidizer®, for nanosizing polarized blue scorpion venom andpolarized alpha lipoic acid.

FIG. 2 is a graph of the raw data displayed in FIG. 3 of an analysis ofthe particle size (μm) of the alpha lipoic acid before particle sizereduction.

FIG. 3 is an illustration showing the raw data used to create the graphin FIG. 2.

FIG. 4 is a graph of the raw data displayed in FIG. 5 of an analysis ofthe particle size (μm) of the alpha lipoic acid after particle sizereduction.

FIG. 5 is an illustration showing the raw data used to create the graphin FIG. 4.

FIG. 6 is a graph of the raw data displayed in FIG. 7 of an analysis ofthe particle size (μm) of the escozine (scorpion venom) after particlesize reduction.

FIG. 7 is an illustration showing the raw data used to create the graphin FIG. 6.

FIG. 8 is a graph of the raw data displayed in FIG. 9 of an analysis ofthe particle size (μm) of the escozine (scorpion venom) before particlesize reduction.

FIG. 9 is an illustration showing the raw data used to create the graphin FIG. 8.

FIG. 10 is a graph that overlays data showing the overall effectivenessof repigmentation after using a blue scorpion venom composition.

FIG. 11 is a graph that overlays data showing the progression ofrepigmentation after using a blue scorpion venom composition.

DETAILED DESCRIPTION

In the following detailed description of various embodiments of thedisclosure, numerous specific details are set forth in order to providea thorough understanding of various aspects of one or more embodimentsof the disclosure. However, one or more embodiments of the disclosuremay be practiced without some or all of these specific details. In otherinstances, well-known methods, procedures, and/or components have notbeen described in detail so as not to unnecessarily obscure aspects ofembodiments of the disclosure.

While multiple embodiments are disclosed, still other embodiments of thepresent disclosure will become apparent to those skilled in the art fromthe following detailed description, which shows and describesillustrative embodiments of the disclosure. As will be realized, thedisclosure is capable of modifications in various obvious aspects, allwithout departing from the spirit and scope of the present disclosure.Accordingly, the figures, and the detailed descriptions thereof, are tobe regarded as illustrative in nature and not restrictive. Also, thereference or non-reference to a particular embodiment of the disclosureshall not be interpreted to limit the scope of the disclosure.

As used herein, the terms “approximately” and “about” generally refer toa deviance of within 5% of the indicated number or range of numbers. Inone embodiment, the term “approximately” and “about”, may refer to adeviance of between 1-10% from the indicated number or range of numbers.

As used herein, the term “particle size reduction machine” generallyrefers to a machine that reduces the particle size of a homogenizedcomposition. One type of particle size reduction machine is aMicrofluidizer®, which uses fluid pressure and shear forces to achieveuniform target nanoparticle size.

The present disclosure discloses a scorpion venom composition, a methodof manufacture thereof, and a method of administration of thatcomposition for treating Vitiligo.

The present disclosure discloses a scorpion venom composition, a methodof manufacture thereof, and a method of administration of thatcomposition for treating acne, eczema, hives (urticarial), pityriasisrosea, psoriasis, rosacea, shingles (herpes zoster).

The active ingredients of the composition are polarized and nanosizedblue scorpion venom and polarized and nanosized alpha lipoic acid. Thecomposition may also be referred to as Adios Vitiligo.

Blue scorpion venom is obtained from the venom of Rhopalurus junceus,also referred to as blue scorpion. The venom is preferably extractedfrom a bioterium of blue scorpions in order to obtain the quantity ofvenom necessary to produce an organic, natural, and health composition.

The blue scorpion venom is a complex mixture of salts, small molecules,peptides, and other proteins. A laboratory may filter the blue scorpionvenom using a glass fiber membrane filter that is preferably 0.80 μm, 25mm, 1 pk/50 pcs. These parameters may ensure the sterilization andpurification of the blue scorpion venom. After filtration, the bluescorpion venom may be combined with chilled, medical-quality distilledwater to achieve a specifically maintained concentration within asterilized environment. Preferably, the dilute blue scorpion venomcontains 0.0003 ml of venom per 0.9997 ml of distilled water (totaling 1ml of prepared dilute solution) for treatment of Vitiligo.

Polarization of the Dilute Blue Scorpion Venom and Alpha Lipoic Acid.Preferably, the dilute blue scorpion venom and alpha lipoic acid arepolarized separately. The preferred process for polarizing dilute bluescorpion venom and alpha lipoic acid is the Mikaelian Polarized LiquidProcess, named after the current inventor. The first steps in thepolarization process, preferably, may be to circulate the dilute bluescorpion venom or alpha lipoic acid repeatedly through plastic or glasstubes. Preferably, the tubes may be one and a half (1.5) centimeters indiameter, but they may be any diameter, and may be made from anymalleable or rigid, non-metallic material. The circulation may beperformed by one or more small pumps. The next step of the process maybe to place, along the pump or tubes, a series of flat magnets.Preferably these magnets may be placed in pairs along the opposite sidesof the tubes and may be aligned so that the negative poles and positivepoles of the magnets mirror one another so that the magnets repel oneanother. The magnets may be then compressed with one or morenon-metallic, preferably wooden, clamps so that the magnets remain inplace. The magnets may be compressed to within two millimeters of oneanother, also compressing the tubes so that the water must flow througha small gap between the magnets. Two millimeters is a preferredcompression point, any greater or lesser compression point may be used,so long as the liquid can flow within the tube, without deviating fromthe scope of the disclosure. Preferably, the dilute blue scorpion venomor alpha lipoic acid may be circulated through this tube lined withpairs of magnets for an extended period of time. The resulting polarizedliquid, compared to non-polarized liquid, may be absorbed far morerapidly into the human and may be significantly more bio-available on acellular level, resulting in significantly improved results.

Polarization, also called wave polarization, is an expression of theorientation of the lines of electric flux in an electromagnetic field(EM field). Polarization technology has been widely used in differentindustries such as radio transmissions, wireless communication systems,food industry, sun glasses, etc. Polarization can be used on manydifferent compounds. By finding the specific molecular frequency, usingthe Mikaelian method, a resonance effect can be achieved that can modifythe quality of the product without changing its molecular structure.Using a resonance effect can increase and/or decrease the potency ofmolecules depending on the frequency used.

In the present methods and compositions, each pair of rare earth magnetsmay be two BLP2-6120-110 magnets with similar polarities. The north poleof the magnet may be determined, such as with a compass, and marked onthe magnet. Each pair of magnets is aligned such that their north polesare in a mirror position, which causes the magnets to repel each other.Once the magnets are placed so as to sandwich a tube for circulating afluid, the magnets may be connected to a power source, such a Chroma®61501 AC power source. This allows the setting of the frequencies of themagnets. The power source preferably provides 500 VA single-phase, 0-300VAC or 0-424 VDC output. At full power, the power source may deliver upto 6:1 Crest Factor loads, DC/15 Hz to 1 kHz. The magnets may beelectromagnets or permanent rare earth magnets.

After the venom and alpha lipoic acid are polarized, the polarizationmay be tested using a polarimeter, such as an Autopol V Pluspolarimeter. In this manner the molecular rotation angle may bedetermined.

A liquid polarized using this method is one that is created usingintense magnetic resistance (IMR). The IMR uses magnetic repulsion andthe fluids circulating through the IMR filed are subject to maolecularpolarization that strongly affects the geometric relationships betweenthe molecules the electromagnetic fields surrounding those molecules.This effect is commercially significant.

FIG. 1 is an illustration of a particle reduction machine 100 fornanosizing polarized blue scorpion venom and polarized alpha lipoicacid. As shown in FIG. 1, either polarized blue scorpion venom orpolarized alpha lipoic acid may be input into an inlet reservoir 105that supports high solid content. A high-pressure pump 110 may generateforces up to 40,000 psi (2578 bar) to force the polarized blue scorpionvenom or polarized alpha lipoic acid stream into precisely engineeredmicrochannels within a fixed-geometry interaction chamber 115. Becauseparticle reduction technology has the ability to control shear rates,the smallest pressure required is typically used.

Once inside the interaction chamber 115, the polarized blue scorpionvenom or polarized alpha lipoic acid may be exposed to consistent andintense impact and shear forces before it is immediately cooled. Thisrepeatable process may result in tiny particles with a uniformdistribution.

Table 1 shows the particle size (μm) of alpha lipoic acid beforeparticle size reduction.

TABLE 1 D(v, 0.1): 5.13235 (μm) D(v, 0.5): 7.67725 (μm) Result File NameAlpha Lipoic Acid D(v, 0.9): 11.35496 (μm) Transmittance (R) 93.2%Transmittance (B) 93.5% Refractive index (R) 1.54-0.00i(1.33)[1.54-0.00(1.540-0.000i), 1.33 (1.333)] Distribution Base VolumeUltrasound 00:15 (1) Circulation speed  5 Agitation speed  2 Convergencefactor 15 Algorithm General Mode

FIG. 2 is a graph of the raw data displayed in FIG. 3 of an analysis ofthe particle size (μm) of the alpha lipoic acid before particle sizereduction.

FIG. 3 is an illustration showing the raw data used to create the graphin FIG. 2.

Table 2 shows the particle size (μm) of alpha lipoic acid after particlesize reduction.

TABLE 2 D(v, 0.1): 1.59409 (μm) Alpha Lipoic D(v, 0.5): 3.99677 (μm)Result File Name Acid (Nanosized) D(v, 0.9): 7.60579 (μm) Transmittance(R) 96.6% Transmittance (B) 95.3% Refractive indecx 1.54-0.00i(1.33) (R)[1.54-0.00(1.540-0.000i), 1.33 (1.333)] Distribution Base VolumeUltrasound 00:27 (1) Circulation speed  5 Agitation speed  2 Convergence15 factor Algorithm General Mode

FIG. 4 is a graph of the raw data displayed in FIG. 5 of an analysis ofthe particle size (μm) of the alpha lipoic acid after particle sizereduction.

FIG. 5 is an illustration showing the raw data used to create the graphin FIG. 4.

Table 3 shows the particle size (μm) of blue scorpion venom afterparticle size reduction.

TABLE 3 D(v, 0.1): 0.05961 (μm) Escozine (0.003) D(v, 0.5): 0.07907 (μm)Result File Name (Nanosized) D(v, 0.9): 0.11126 (μm) Transmittance (R)98.2% Transmittance (B) 86.5% Refractive index (R) 1.54-0.00i(1.33)[1.54-0.00(1.540-0.000i), 1.33 (1.333)] Distribution Base VolumeUltrasound Off Circulation speed  5 Agitation speed  2 Convergencefactor 15 Algorithm General Mode

FIG. 6 is a graph of the raw data displayed in FIG. 7 of an analysis ofthe particle size (μm) of the escozine (scorpion venom) after particlesize reduction.

FIG. 7 is an illustration showing the raw data used to create the graphin FIG. 6.

Table 4 shows the particle size (μm) of blue scorpion venom beforeparticle size reduction.

TABLE 4 D(v, 0.1): 6.33306 (μm) Escozine (0.003) D(v, 0.5): 67.38076(μm) Result File Name (Non-Nanosized) D(v, 0.9): 144.79427 (μm)Transmittance (R) 98.1% Transmittance (B) 95.2% Refractive indecx1.54-0.00i(1.33) (R) [1.54-0.00(1.540-0.000i), 1.33 (1.333)]Distribution Base Volume Ultrasound Off Circulation speed  5 Agitationspeed  2 Convergence 15 factor Algorithm General Mode

FIG. 8 is a graph of the raw data displayed in FIG. 9 of an analysis ofthe particle size (μm) of the escozine (scorpion venom) before particlesize reduction.

FIG. 9 is an illustration showing the raw data used to create the graphin FIG. 8.

Table 5 shows the preferred amount of one or more vitamins and mineralsof one embodiment of the composition. The vitamins and minerals may becombined with the active ingredients, polarized and nanosized bluescorpion venom and polarized and nanosized alpha lipoic acid, and/orminerals to create the final composition. Table 5 also lists amountrange (g/ml), weight range (%), and preferred weight range (%). This isbased on a 450 ml bottle of final product

TABLE 5 Amount Preferred Wt/Wt % Preferred Ingredient Range Amount RangeWt/Wt % Phase I Purified Water 0.10-4.0 ml 2.01 ml   0.01-2.0 0.43Potassium Sorbate .05-3.0 g 0.85 g   0.01-2.0 0.18 Glycerin (99.7%)50-120 g 86.09 g    1.0-40 18.20 Potassium Benzoate 0.02-2.0 g 0.47 g  0.01-2.0 0.10 Alpha Lipoic Acid 0.01-5.0 g 1.58 g   0.01-2.0 0.33Phase II Fructose Crystalline 20-200 g 103.11 g    1.0-40 21.80Glutathione 1.0-20 g 9.46 g   0.01-5.0 2.00 Vitamin C Ascorbic 0.3-10 g3.15 g   0.01-5.0 0.67 Acid   Vitamin B1 0.3-10 g 1.89 g   0.01-5.0 0.40Thiamine HCl   Vitamin B6 0.3-10 g 3.15 g   0.01-5.0 0.67 Pyridoxal-5-Phosphate   Vitamin B12 0.001-1.0 g 0.03 g  0.001-5.0 0.01Cyanocobalamin   Vitamin B12 0.001-1.0 g 0.03 g  0.001-5.0 0.01Hydroxocobalmin   Vitamin B12 0.001-1.0 g 0.05 g  0.001-5.0 0.01Methylcobalamin   Vitamin E 0.1-50 g 11.47 g   0.01-5.0 2.42 Tocopheryl1,100 IU/gm   Vitamin 0.01-5.0 g 0.32 g  0.001-2.0 0.07 D3 1000,000IU/gm   LoHan Guo Extract 0.01-5.0 g 0.57 g  0.001-2.0 0.12 ZincGluconate 10% 0.3-10 g 3.15 g  0.001-3.0 0.67 Copper 0.01-5.0 g 0.16 g 0.001-2.0 0.3 Gluconate 10% Vitamin H/Vitamin 0.1-20 g 7.88 g 0.001-5.0 1.67 B7 Biotin 1%   Vitamin B3 0.3-10 g 3.15 g  0.001-3.00.67 Niacinamide Orange Pineapple 0.3-10 g 1.18 g 0.0001-0.2 0.25 FlavorGrape Concentrate 1.0-50 g 14.19 g  0.001-9.0 3.00 Cherry Concentrate1.0-50 g 14.19 g  0.001-9.0 3.00 Citric Acid 0.01-5.0 g 0.61 g 0.001-5.0 0.13 Xanthan Gum 0.01-5.0 g 0.71 g  0.001-5.0 0.15Resveratrol 0.3-10 g 3.15 g  0.001-5.0 0.67 Hyaluronic Acid 0.3-10 g1.89 g  0.001-5.0 0.40 Purified Water 50-400 ml 198.49 ml   0.1-80 41.96

In one embodiment, polarization of the active ingredients, alpha lipoicacid and blue scorpion venom, may be performed. Next, nanoparticlereduction of the active ingredients may be performed. The polarized andnanosized active ingredients may then be mixed and a final weightrecorded and prepared for shipment to a manufacturing facility. Themanufacturing facility may prepare the polarized and nanosized activeingredient mixture for identification, sample labeling, and microbiologytesting. Next, the inactive ingredients listed in Phase I of Table 5 maybe weighed. Then the alpha lipoic acid and glycerin 99.7% of Phase I maybe added to a first mixing vessel and blended until the mixture hasbecome homogenous. Next, the remaining ingredients of Phase I, purifiedwater, potassium sorbate, and potassium benzoate, may be added to asecond mixing vessel and blended until the mixture has becomehomogenous. The ingredients from the first mixing vessel and the secondmixing vessel may be combined and blended until a final Phase I mixturehas become homogenous.

Next, the inactive ingredients of Phase II of Table 5 may be weighed.Then all of the ingredients from Phase II, except for the citric acid,may be slowly added the mixing vessel containing the final Phase Imixture, until the final composition is formed. The mixing vessel may beblended until the final composition has become homogenous. At thispoint, the pH of the final composition is tested by adding the citricacid ingredient from Phase II until a target pH of 3.81 is reached.

A bulk version of the composition may be transferred into a sealed,sterilized bulk container and the container then transferred into to arefrigerated environment. The composition is preferably refrigerated andmaintained at a range between 12 to 14 C (52 F-58 F). Blue scorpionvenom may degrade at an accelerated rate when exposed to bright lightand thus the dark refrigerated storage environment should be protectedfrom light and without internal illumination. Further, the compositionhas tendency to separate from water when suspended in water for anextended period of time. To achieve consistent concentration of thecomposition, the sealed bulk container is preferably agitated in a backand forth manner for no less than 30 minutes before being transferredinto individual containers. During the packaging process the bulkcontainer should be continuously agitated through stirring.

The final step of the process is packaging and bottling. The bulkcomposition is transferred in a sterilized environment into individualone liter bottles, which should include labels, air-tight seals, andopaque containers, which protect the composition from degradation due toinappropriate exposure to light. The containers are pre-sterilizedbefore being filled with the composition. The process of packaging istime sensitive. Undo exposure to air and excessive temperatures willundermine the potency of the composition. As such, time is a sensitiveissue with the product. Exposed to room temperature, the process cannotbe extended past a few (approximately four) hours from removal fromrefrigeration to completion of bottling. However, if bottling is done ina highly air conditioned environment (lower than 15 C or 58 F) or if thedistilled water used in production is chilled (through priorrefrigeration) then the period of production from removal fromrefrigeration to finalized bottling can be extended. Eight (8) hours forhighly chilled distilled water; twelve (12) hours for highlyrefrigerated environment.

Once the bottling procedure is complete, bottles of the finalcomposition are to be stored in a dark, refrigerated environmentmaintained, as preferred, at a temperature between 12 and 14 C (52 F and58 F) where they will wait until final shipping.

The bottle may comprise 450 mL of the final composition. A single doseof the final composition may be a 15 mL dose. The 15 mL dose maycomprise 0.00005 to 0.00015 mL of blue scorpion venom. There may be0.0001 mL blue scorpion venom in the 15 mL dose. The 15 mL dose maycomprise 0.04 to 0.06 g of alpha lipoic acid. There may be 0.0527 g ofalpha lipoic acid in the 15 mL dose. The 15 mL dose may also comprise:

TABLE 6 Range One Embodiment Component of 15 mL dose (in grams) (ingrams) Biotin    0.2-0.5 0.2628 Cherry Flavoring    0.3-0.6 0.4730Citric Acid   0.01-0.04 0.0205 Copper Gluconate  0.003-0.007 0.0053Crystalline Fructose   3.2-3.6 3.4371 Glutathione   0.2-0.4 0.3153Glycerin   2.5-3.2 2.8695 Grape Flavoring   0.4-0.5 0.4730 HyaluronicAcid   0.04-0.08 0.0631 LoHan Guo Extract   0.01-0.03 0.0189 OrangePineapple Flavoring   0.01-0.05 0.0394 Potassium Benzoate   0.01-0.250.0158 Potassium Sorbate   0.02-0.04 0.0284 Purified Water    12-13 mL12.7208 mL Resveratrol   0.05-0.2 0.1051 Vitamin B1   0.04-0.08 0.0631Vitamin B12 0.0005-0.0018 0.0011 (cyanobalamin) Vitamin B120.0005-0.0018 0.0011 (hydroxocobalmin) Vitamin B12  0.001-0.0025 0.0016(methylcobalamin) Vitamin B3  0.05-0.2 0.1051 Vitamin B6  0.05-0.20.1051 Vitamin C  0.05-0.2 0.1051 Vitamin D3  0.005-0.020 0.0105 VitaminE   0.3-0.6 0.3822 Xanthan Gum  0.01-0.04 0.0237 Zinc Gluconate 0.05-0.25 0.1051

The composition is preferably tested for bacterial contaminants,chemical contaminants, and concentration. Standard microbial and massspectrometry tests are preferably used. If possible, no product shouldbe shipped to a customer until the batch has undergone testing forpurity.

Standard testing procedures, such as Lowry's method for determiningprotein concentration should be used to quantitatively evaluate thecomposition. Other types of procedures, known in the art, may also beused. Batches should be rejected if bacterial or chemical contaminantsare found, or if more than 5% of the bottles test for levels of anychemical naturally found within the blue scorpion venom, but at a higheror lower concentration in excess of 10% deviation from the standardconcentration per standardized mass spectrometry of the blue scorpionvenom.

FIG. 10 is a graph 200 which overlays data showing the overalleffectiveness of repigmentation in study patients after treatment withthe composition. In this study, men and women, ranging from 5 to 80years old, who were suffering from Vitiligo were chosen as patients. Aspart of the treatment regimen, each patient orally ingested twomilliliters (2 cc) of the composition, twice a day, over the course of90 days. The patients were monitored once before starting the intake,and then monitored once a month thereafter to evaluate the effectivenessof the composition by observing changes to pigmentation on the patient'sskin. As shown in FIG. 2, within 30 days of treatment with thecomposition, 29 individuals had recovery of pigmentation up to 20%.Within 60 days of treatment, 64 individuals had recovery of pigmentationup to 40%. Within 90 days of treatment, 23 individuals had recovery ofpigmentation up to 60%. Further, within 90 days of treatment, only 4individuals did not see any results. Overall, most patients beganexperiencing an increase in pigmentation ranging from 15% to 60% withinthe first three months of treatment. No signs of allergic reactions ornegative side effects were observed in any of the patients. Further, thepatients showed adequate tolerance to the composition and did notdevelop any complications.

FIG. 11 is a graph 300 which overlays data showing the progression ofrepigmentation after using the composition. As shown in FIG. 3, within30 days of treatment with the composition, 35 patients reported positiverepigmentation results. Within 60 days of treatment, 85 patientsreported positive repigmentation results. And within 90 days oftreatment, 116 patients reported positive repigmentation results. Thus,it may be concluded that the composition is highly effective atenhancing re-pigmentation and may be used as or part of a treatmentregimen for patients suffering for Vitiligo.

Unless otherwise stated, all measurements, values, ratings, positions,magnitudes, sizes, locations, and other specifications that are setforth in this specification, including in the claims that follow, areapproximate, not exact. They are intended to have a reasonable rangethat is consistent with the functions to which they relate and with whatis customary in the art to which they pertain.

The foregoing description of the preferred embodiment has been presentedfor the purposes of illustration and description. While multipleembodiments are disclosed, still other embodiments will become apparentto those skilled in the art from the above detailed description. Theseembodiments are capable of modifications in various obvious aspects, allwithout departing from the spirit and scope of protection. Accordingly,the detailed description is to be regarded as illustrative in nature andnot restrictive. Also, although not explicitly recited, one or moreembodiments may be practiced in combination or conjunction with oneanother. Furthermore, the reference or non-reference to a particularembodiment shall not be interpreted to limit the scope of protection. Itis intended that the scope of protection not be limited by this detaileddescription, but by the claims and the equivalents to the claims thatare appended hereto.

Except as stated immediately above, nothing that has been stated orillustrated is intended or should be interpreted to cause a dedicationof any component, step, feature, object, benefit, advantage, orequivalent, to the public, regardless of whether it is or is not recitedin the claims.

What is claimed is:
 1. A composition, said composition comprising: ablue scorpion venom; and an alpha lipoic acid.
 2. The composition ofclaim 1, wherein said blue scorpion venom is diluted in a distilledwater, such that a dilute blue scorpion venom is created; wherein saiddilute blue scorpion venom is polarized, such that a polarized bluescorpion venom is created; and wherein said alpha lipoic acid ispolarized, such that a polarized alpha lipoic acid is created.
 3. Thecomposition of claim 2, wherein said polarized blue scorpion venom ispolarized by circulating said dilute blue scorpion venom between atleast one set of two paired and aligned magnets; and wherein said alphalipoic acid is polarized by circulating said alpha lipoic acid betweensaid at least one set of two paired and aligned magnets.
 4. Thecomposition of claim 3, wherein each set of magnets of said at least oneset of two paired and aligned magnets mirror each other, such that saidmagnets repel each other.
 5. The composition of claim 4, wherein saidpolarized blue scorpion venom and said polarized alpha lipoic acid arenanosized.
 6. The composition of claim 5, wherein a particle sizereduction machine is used to nanosize said polarized blue scorpion venomand said polarized alpha lipoic acid, such that a polarized andnanosized. blue scorpion venom is created and a polarized and nanosizedalpha lipoic acid is created.
 7. The composition of claim 6, whereinsaid at least one set of two paired and aligned magnets are operativelycoupled to a power source, such that a frequency of said at least oneset of two paired and aligned magnets is set.
 8. The composition ofclaim 7, wherein said polarized and nanosized blue scorpion venom andsaid polarized and nanosized alpha lipoic acid comprise two activeingredients of said composition, and wherein said composition isingested orally by a patient suffering from vitiligo as part of atreatment regimen, such that said patient's skin has an enhancedre-pigmentation.
 9. The composition of claim 8, wherein said compositionfurther comprises: one or more vitamins.
 10. The composition of claim 9,wherein said one or more vitamins comprise: vitamin B1; vitamin B3;vitamin B6; vitamin B7; vitamin B12; vitamin C; vitamin D3; and vitaminE.
 11. The composition of claim 8, further comprising: one or moreminerals.
 12. The composition of claim 11, wherein said one or moreminerals comprise: zinc gluconate; copper gluconate; potassium sorbate;and potassium benzoate.
 13. The composition of claim 8, wherein saidpolarized and nanosized blue scorpion venom is in an amount from 0.00005to 0.00015 mL in an approximately 15 mL dose of said composition. 14.The composition of claim 13, wherein said polarized and nanosized bluescorpion venom is in an amount of 0.0001 mL in an approximately 15 mLdose of said composition.
 15. The composition of claim 8, wherein saidpolarized and nanosized alpha lipoic acid is in an amount from 0.04 to0.06 g in an approximately 15 mL dose of said composition.
 16. Thecomposition of claim 15, wherein said polarized and nanosized alphalipoic acid is in an amount of 0.06 g an approximately 15 mL dose ofsaid composition.
 17. A method of treating a condition comprising thesteps: creating a condition treatment composition comprising: a bluescorpion venom and an alpha lipoic acid; wherein said conditiontreatment composition is ingested orally by a patient suffering fromvitiligo as part of a treatment regimen, such that said patient's skinhas an enhanced re-pigmentation.
 18. The method of claim 17, furthercomprising the steps: diluting said blue scorpion venom to create adilute blue scorpion venom; polarizing said dilute blue scorpion venomto create a polarized blue scorpion venom; polarizing said alpha lipoicacid to create a polarized alpha lipoic acid.
 19. The method of claim18, further comprising the steps: nanosizing said polarized bluescorpion venom to create a polarized and nanosized blue scorpion venom;nanosizing said polarized alpha lipoic acid to create a polarized andnanosized alpha lipoic acid;
 20. The method of claim 19, wherein saidpolarized blue scorpion venom and said polarized alpha lipoic acid arepolarized by a polarization method comprising the steps: providing oneor more tubes that are configured to allow said polarized blue scorpionvenom or said polarized alpha lipoic acid to circulate through;providing one or more pairs of magnets, wherein each pair of said one ormore pairs of magnets are aligned and spaced apart, such that one ofsaid one or more tubes is sandwiched between said one or more alignedpairs of magnets; circulating said diluted blue scorpion venom throughsaid one or more tubes; and circulating said alpha lipoic acid throughsaid one or more tubes; wherein said nanosizing comprises the steps:providing a particle size reduction machine; adding said polarized bluescorpion venom to said particle size reduction machine, such that apolarized and nanosized blue scorpion venom is created; and adding saidpolarized alpha lipoic acid to said particle size reduction machine suchthat a polarized and nanosized alpha lipoic acid is created.